Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
暂无分享,去创建一个
P. De | N. Dey | Xiaoqian Lin | N. Koirala | R. Sulaiman | J. C. Aske | D. Starks | K. Gaster | Luis Rojas Espaillat | Adam P. Dale | Kris Gaster
[1] A. Obradovic. Precision immunotherapy , 2023, Science.
[2] P. De,et al. Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers , 2023, Biomedicines.
[3] Ryan D. Chow,et al. Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma. , 2022, Cancer discovery.
[4] Do Young Hyeon,et al. PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer , 2022, Nature Communications.
[5] X. Matías-Guiu,et al. Facts and hopes in immunotherapy of endometrial cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] P. De,et al. Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance , 2022, Cancers.
[7] A. Tinker,et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.
[8] X. Guan,et al. Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy against Metastatic Tumors , 2021, Advanced healthcare materials.
[9] Songfa Zhang,et al. PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance , 2021, Cancer management and research.
[10] Chen Liang,et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.
[11] P. De,et al. Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy , 2021, Cancers.
[12] A. Jennifer,et al. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime , 2021, International journal of molecular sciences.
[13] Qin Luo,et al. Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway , 2021, Neoplasia.
[14] R. Scolyer,et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. , 2020, Pathology.
[15] M. Stoler,et al. PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas , 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[16] Joel s. Brown,et al. The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer , 2020, Dynamic Games and Applications.
[17] A. Tinker,et al. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer , 2020, JAMA oncology.
[18] W. McCluggage,et al. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas , 2020, Virchows Archiv.
[19] D. Tuveson,et al. DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. , 2020, Physiological reviews.
[20] N. Zhang,et al. Extracellular vesicle encapsulated microRNA-320a inhibits endometrial cancer by suppression of the HIF1α/VEGFA axis. , 2020, Experimental cell research.
[21] T. Bosse,et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. , 2020, Critical reviews in oncology/hematology.
[22] A. Mills,et al. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas , 2020, International Journal of Gynecological Cancer.
[23] Yuanting Gu,et al. Cancer-associated fibroblasts-derived exosomes suppresses immune cell function in breast cancer via miR-92/PD-L1 pathway , 2020 .
[24] E. Schmidt,et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. Satoh,et al. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas , 2020, BMC Cancer.
[26] L. Diaz,et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] P. Vahteristo,et al. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells , 2019, The American journal of surgical pathology.
[28] E. Schmidt,et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.
[29] A. Chinnaiyan,et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression , 2018, The Journal of clinical investigation.
[30] J. Taube,et al. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.
[31] David Basanta,et al. Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer , 2017, Nature Ecology & Evolution.
[32] Freeman,et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity , 2017, The Journal of experimental medicine.
[33] A. Mills,et al. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors , 2017, The American journal of surgical pathology.
[34] Robert R Yauch,et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice , 2017, Nature Communications.
[35] I. S. Omar,et al. Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway. , 2016, American journal of cancer research.
[36] D. Olive,et al. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage , 2015, Oncoimmunology.
[37] Y. Woo,et al. Cancer-Associated Fibroblasts Promote Proliferation of Endometrial Cancer Cells , 2013, PloS one.
[38] A. Chinnaiyan,et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. , 2018, The Journal of clinical investigation.